Exploring the molecular determinants of substrate-selective inhibition of cyclooxygenase-2 by lumiracoxib.
A.B. Hancock Jr. Memorial Laboratory for Cancer Research, Department of Biochemistry, Department of Chemistry, Department of Pharmacology, Vanderbilt Institute of Chemical Biology, Center in Molecular Toxicology, and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, United States.
Copyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.
COX-2, Endocannabinoids, Lumiracoxib, Prostaglandins, Substrate-selective inhibition
- [PubMed – as supplied by publisher]